Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The AMPLITUDE phase 3 trial shows adding niraparib to abiraterone‑prednisone improves radiographic progression‑free survival in HRR‑deficient metastatic castration‑sensitive prostate cancer, with greater benefit in BRCA‑altered disease but
Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported qual
The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safet
One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety
A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall surviva
![[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis](https://news.medxy.ai/wp-content/uploads/2025/11/9d3c0201-d1b3-49f2-a408-3ea3d0347451-600x600.jpg)
PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.
In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.
Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematol
Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but
The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased tox
The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.
A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survi
This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease
This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balanc
Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains
This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immun
Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.
This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.
Open language-specific specialty feeds and department pages.